Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

For People Who Invest a Lot of Money in Stocks
Epic Wealth Bundle

Access Stock Recommendations from Our 4 Premium Services


See Full Details

**Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.

AD

3 Nifty 500 Stocks at 52-week Highs

May 19, 2026

3 Nifty 500 Stocks At 52-week HighsImage source: jadamprostore/www.istockphoto.com

While the broader market continues to trade flat and the benchmark indices are trading in a tight band, several Nifty 500 stocks are hitting fresh 52-week highs.

This shows investors are becoming very choosy and are rewarding companies that have good earnings visibility, sectoral tailwinds, strong order books or structural growth themes.

So, though the market is volatile, stocks related to capital markets, pharma and cables are showing relative strength.

Such resilience is often a sign of institutional accumulation, but investors should be wary as stocks at lifetime or 52-week highs can also see sharp profit-booking if earnings momentum does not hold.

Here are 3 stocks from the Nifty 500 that have hit 52-week highs.

#1 Gland Pharma

First on the list is the stock of Gland Pharma.

Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing generic injectables manufacturing companies.

It has a global footprint across 60 countries, including the US, Europe, Canada, Australia, India, and other markets.

The stock of Gland Pharma hit a new 52-week high of Rs 2,225 on 19 May 2026. The company is a part of the Nifty 500.

One of the reasons for the recent surge in the stock price could be the Q4 FY26 performance. The company reported revenue during the period of Rs 17,428 m, which surged 22%. The net profits of Gland jumped 97% to Rs 3,667 m YoY.

In terms of business updates, Gland Pharma has launched five molecules in the USA in Q4 FY26, including Dalbavancin, Brimonidine etc. During FY26, 31 products were launched in the US.

In an earnings presentation of 15 May 2026, the company has stated that it has filed 21 ready to use infusion bag products and received approval for 18 so far.

An additional 11 are currently under development. Total RTU bag portfolio addresses the market opportunity of approximately US$ 634 m for Gland Pharma.

In FY26, the company also signed a complex Nano Drug Delivery System based Injectable contract in oncology with a large pharma company.

Overall, Gland Pharma looks well-positioned for steady long-term growth if execution in complex injectables, CDMO expansion, and GLP-1 opportunities continues successfully.

However, investors must remind themselves that the stock has hit a new 52-week high.

How Gland Pharma Stock Has Performed Recently

Gland Pharma shares jumped to Rs 2,218 from Rs 1,829 in the past five trading sessions.

The stock touched its 52-week high of Rs 2,255 on 19 May 2026 and its 52-week low of Rs 1,453 on 19 May 2025.

Gland Pharma Share Price - 1 Month

Want To Read The Full Article?

Enter your email to continue reading on Equitymaster.

Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster covering exciting investing ideas and opportunities in India.

Equitymaster requests your view! Post a comment on "3 Nifty 500 Stocks at 52-week Highs". Click here!